Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-06-25 | Direct | 5,860 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 5,860 · Balance 5,860 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:37 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001610717-26-000304 · form4.xml · derivative · entry 1 Chavez Margarita · CIK 0002032496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:29 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001610717-25-000255 · form4.xml · derivative · entry 1 Chavez Margarita · CIK 0002032496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2035-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:09 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001610717-24-000423 · form4.xml · derivative · entry 1 Chavez Margarita · CIK 0002032496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2034-08-07 F1 · derivative.exercise_date: 1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.